Search
Navitoclax
go.drugbank.com/drugs/DB12340InvestigationalNavitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer. … Navitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies,
Synonyms: (R)-4-(3-Morpholin-4-Yl-1-Phenylsulfanylmethyl-Propylamino)-N-(4-{4-[2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-Enylmethyl]-Piperazin-1-Yl}-Benzoyl)-3-TrifluoromethanesulfonylbenzenesulfonamideChulaCov19 mRNA vaccine
go.drugbank.com/drugs/DB16445ExperimentalThe next phase of this study is for phase I and II clinical trials (NCT04566276) beginning in January 2021. … The ChulaCov19 vaccine is mRNA-based and was developed in Thailand’s Chulalongkorn University in collaboration with the University of Pennsylvania in the US[L30673, L30678].
Inarigivir soproxil
go.drugbank.com/drugs/DB15063InvestigationalInarigivir soproxil is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic
VPM1002
go.drugbank.com/drugs/DB15801InvestigationalVPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other … This recombinant BCG, VPM1002, has been created in response and investigated for preventing pulmonary TB in newborns and TB recurrence in adults through post-exposure immunization.
Mesenchymal stem cell-derived exosomes
go.drugbank.com/drugs/DB24445InvestigationalMesenchymal Stem Cell-Derived Exosomes is under investigation in clinical trial NCT07183384 (MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction). … Mesenchymal Stem Cell-Derived Exosomes is a biologic drug.
Ralmitaront
go.drugbank.com/drugs/DB19128InvestigationalRalmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or
Synonyms: 1h-pyrazole-3-carboxamide, 5-ethyl-4-methyl-n-(4-(2s)-2-morpholinylphenyl)-, 5-ethyl-4-methyl-n-(4-((2s)-morpholin-2-yl)phenyl)-1h-pyrazole-3-carboxamideOlprinone
go.drugbank.com/drugs/DB16847InvestigationalCategories: Compounds used in a research, industrial, or household settingMonofluorophosphate ion
go.drugbank.com/drugs/DB02348ExperimentalCategories: Compounds used in a research, industrial, or household settingBarbexaclone
go.drugbank.com/drugs/DB09001ExperimentalWith this difference in potency in mind, other pharmacokinetic considerations such as dose titration, daily dosing, and optimal plasma concentration can be considered the same as for the equivalent amount … These reports were conducted in a small series of patients in the 1970s and 1980s, and have yet to be confirmed by larger controlled trials.
ALMB-0166
go.drugbank.com/drugs/DB17937InvestigationalALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of acute spinal cord injury. It was granted FDA orphan designation in November 2018.[L47067]